Use of this tumour model, in which rejection depends mainly on these tumour-specific CD8+ T cells [42–44], allowed us to evaluate whether MNPs and EMFs could increase retention of these CD8+ T cells in the tumour and, if so, whether this led to improved treatment efficacy. The gene discussed is CD8A; the disease is neoplasm.